Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Blood

Volumn 107, Issue 3, 2006, Pages 885-891

  Eichhorst, Barbara F ^b   Busch, Raymonde ^b   Hopfinger, Georg ^b   Pasold, Rita ^b   Hensel, Manfred ^b   Steinbrecher, Cordelia ^b   Siehl, Siegfried ^b   Jäger, Ulrich ^b   Bergmann, Manuela ^b   Stilgenbauer, Stephan ^b   Schweighofer, Carmen ^b   Wendtner, Clemens M ^b   Döhner, Hartmut ^b   Brittinger, Günter ^b   Emmerich, Bertold ^b   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKEMIA REMISSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

EID: 31544434508     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2395     Document Type: Article

References (23)

1. French Cooperative Group on CLL, Johnson S, Smith AG, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: the French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
2. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
3. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
4. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999;94:2836-2843.
5. Pellacani A, Tosi P, Zinzani PL, et al. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 1999;33:147-153.
6. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.
7. Cazin B, Lepretre S, Travade P, et al. Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukaemia (CLL): preliminary data on 75 patients [abstract]. Blood. 2002;100. Abstract 773.
8. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
9. Flinn IW, Byrd JC, Falkson CI, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997. Blood. 2001;98. Abstract 2649.
10. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001;114:342-348.
11. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
12. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
13. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
14. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
15. Flinn IW, Grever MR, Neuberg D, et al. ECOG, Cancer and Leukemia Group B, Southwest Oncology Group: fludarabine and cyclophosphamide produces a significant higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood. 2004;104. Abstract 475.
16. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
17. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
18. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
19. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53.
20. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993;11:1985-1989.
21. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
22. Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia: the possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res. 2005;29:389-395.
23. Catovsky D, Richards S. Incidence in hemolytic anemia after chemotherapy in the CLL4 trial: a possible protective role for fludarabine plus cyclophosphamide. Blood. 2004;104. Abstract 480.